Note: Ingredients listed on restricted chemical lists
EC/CAS
220-120-9/2634-33-5
Name of the chemical
1,2-Benzisothiazol-3(2H)-one
Concentration
<0.05
EC/CAS
55965-84-9
Name of the chemical
Mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)
Concentration
<0.0015
General Information
Version
2.0
Revision date
2022-04-15
Product name
Elasto-Vit
1.2.1 Relevant identified uses
Professional use,Consumer use
Emergency telephone
+32 70 245 245
Icons in SDS
Company Information
company name
Rectavit N.V.
e-mail address of the competent person responsible for the Safety Data Sheet
msds@rectavit.be
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
To our knowledge, this product does not present any particular risk, provided it is handled in accordance with good occupational hygiene and safety practice.
2.2 Label elements
Labelling
Supplemental label elements
EUH208 - Contains 1,2-benzisothiazol-3(2H)-one, reaction mass of 5-chloro-2-methyl-2H- isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1). May produce an allergic reaction. EUH210 - Safety data sheet available on request.
2.3 Other hazards
The product does not meet the PBT and vPvB classification criteria Contains no PBT and/or vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII Component 1,2-benzisothiazol-3(2H)-one (2634-33-5) This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII reaction mass of 5-chloro-2-methyl-2H-isothiazol-3- This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII one and 2-methyl-2H-isothiazol-3-one (3:1) (55965- This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII 84-9) The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
